New Horizon Health Limited provided group earnings guidance for the year ended December 31, 2022. The total revenue of the Group for the year ended December 31, 2022 is expected to be within the range of RMB 750.5 million to RMB 782.5 million, representing an increase in the range of 252.7% to 267.7% from approximately RMB 212.8 million for the year ended December 31, 2021.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.14 HKD | -19.75% | -.--% | -38.92% |
Apr. 08 | New Horizon Health Limited Announces Board Appointments | CI |
Mar. 28 | New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.92% | 813M | |
-11.68% | 11.22B | |
-10.38% | 7.58B | |
+27.58% | 5.48B | |
+1.44% | 5.38B | |
-17.38% | 3.77B | |
+8.12% | 2.6B | |
-64.90% | 2.35B | |
-10.17% | 2.25B | |
+26.75% | 2.2B |
- Stock Market
- Equities
- 6606 Stock
- News New Horizon Health Limited
- New Horizon Health Limited Provides Group Earnings Guidance for the Year Ended December 31, 2022